{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(24)"],"submitter":["Oza AM"],"pubmed_abstract":["<h4>Purpose</h4>Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation, and cell cycle progression. Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting.<h4>Patients and methods</h4>Sequential phase II studies evaluated single-agent activity of temsirolimus in women with recurrent or metastatic chemotherapy-naive or chemotherapy-treated endometrial cancer. Temsirolim"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["3278-85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3158598"],"repository":["biostudies-literature"],"pubmed_title":["Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group."],"pmcid":["PMC3158598"],"pubmed_authors":["Ivy P","Oza AM","Eisenhauer EA","Biagi J","Tsao MS","Kamel-Reid S","Hoskins PJ","Ghatage P","Provencher DM","Gotlieb WH","Dancey JE","Mackay HJ","Mazurka J","Tonkin KS","Sederias J","Elit L"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.","description":"<h4>Purpose</h4>Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation, and cell cycle progression. Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting.<h4>Patients and methods</h4>Sequential phase II studies evaluated single-agent activity of temsirolimus in women with recurrent or metastatic chemotherapy-naive or chemotherapy-treated endometrial cancer. Temsirolim","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Aug","modification":"2025-06-01T12:16:45.2Z","creation":"2019-03-27T00:43:09Z"},"accession":"S-EPMC3158598","cross_references":{"pubmed":["21788564"],"doi":["10.1200/JCO.2010.34.1578","10.1200/jco.2010.34.1578"]}}